Clinical Trials Update: June 14, 2006
Brain Tumor (Pediatric) Lung Cancer Migraine and Cluster Headaches
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Brain Tumor (Pediatric)
The purpose of this study is to find out if treating subjects with the chemotherapy drug topotecan before they get radiation therapy -- along with G-CSF -- improves overall survival. It will also note the effects (good and/or bad) of topotecan on a patient's brainstem tumor.
Volunteers between ages 3 and 21 at the time of diagnosis who have a brainstem glioma may be eligible to participate. Patients will be in this study for about 6-and-a-half weeks.
Follow-up treatment, which includes physical exams and blood tests, will continue for 5 years so that researchers can watch for any effects of treatment.
The research site is in Cincinnati, Ohio.
This trial will evaluate if adding bevicizumab to the current treatment of Tarceva (erlotinib) can increase the effectiveness of the lung cancer treatment.
Patients who qualify for this study should have stage IIIB or stage IV non-small cell lung cancer and have had one type of chemotherapy in the past prior to applying for the study. Individuals may not have untreated cancer that has spread to the brain.
The research site is in Gainesville, Fla.
Migraine and Cluster Headaches
Episodic migraines (2-4 migraines per week), may lead to a condition known as chronic daily headache (head pain that occurs at least 15 days per month).
The purpose of this research study is to see how well the trial drug works to prevent episodic migraine from developing into chronic daily headache. This trial is open to adults between the ages of 18 and 65 who have a history of migraine headaches.
It will take about 10 months for a participant to finish the study.
Research sites are located throughout the United States.
Copyright 2006 Thomson CenterWatch. All rights reserved.